Everything you need to know about the new NHS home smear tests
While nobody likes going for a smear test, screenings are vital in preventing cervical cancer.
Despite the fact cervical screenings save thousands of lives each year in the UK, though, uptake has gradually declined, and nearly a third of eligible women in England didn't attend their most recent test.
The drop has been blamed – when it comes to younger women in particular – on embarrassment, fears over the test causing pain, and a lack of convenient appointments.
So in an effort to combat barriers and potentially reach an additional 400,000 women in England every year, the NHS is set to roll out 'groundbreaking' new DIY screening kits.
After a trial which saw 27,000 YouScreen kits issued to patients who were overdue a smear across London GPs, 85% of those offered one accepted and 56% returned a self-sample.
Lead investigator Dr Anita Lim, from King's College London, said: 'Self-sampling has been hailed as a game-changer.
'It is crucial we make cervical screening easier… to help protect more people from this highly preventable cancer. The YouScreen trial has given us the evidence we need to demonstrate that self-sampling helps get more women screened.'
How do these home kits work, though, and how can you get one?
Dr Raj Arora, a GP specialising in women's health, skincare and mental health, tells Metro.co.uk: 'Essentially these kits are looking to detect Human Papillomavirus (HPV), a virus that causes most cervical cancers.'
They look similar to a Covid-19 lateral flow test, with a long swab which is entered into the vagina. The sample is then put into a test tube and sent to a lab.
'Medical professionals will be able to detect HPV cells to understand if the patient is at risk or suffering from cervical cancer,' Dr Donald Grant, GP and senior clinical advisor at The Independent Pharmacy, tells Metro.co.uk. 'If HPV cells are detected, the patient will be contacted for an in-person cervical screening.'
According to Dr Raj, 'a self-test means that the patient has more control over any potential discomfort and also the test itself can be quicker to carry out,' while Dr Grant highlights: 'Unlike GP smear tests, at-home swabs don't need to touch the cervix, making the process much more painless for women.'
As well as being more convenient, the great news about these self-screenings is that they're just as precise, and pick up the same abnormalities, as tests carried out in your doctor's surgery. There is a caveat, though.
'Studies have shown a similar accuracy to in-clinic cervical screening as long as the test is carried out correctly,' says Dr Raj.
Dr Grant agrees, adding: 'Accurate results largely depend on the user's ability to follow the instructions and correctly collect the swab.'
If the results are of concern or the home test hasn't been administered correctly, further examination by a GP or nurse may be required.
To get the right results, it's vital you follow the instructions on your cervical self-screening kit carefully.
Dr Grant advises caution when handling the sample, commenting: 'As soon as the swab is collected, it should be carefully placed in the provided packaging to avoid skewing the results, allowing for a more accurate diagnosis.
'It's also important to ensure that you rotate the swab for the instructed period of time (around 20-30 seconds) or 5-6 times,' says Dr Raj.
The Department of Health confirmed in a recent announcement that these kits will be available through the NHS from January 2026, and will be offered to women in England who have rarely or never attended cervical screening. More Trending
In the meantime, Home HPV tests can be purchased online through providers such as Check4Cancer and Superdrug Online Doctor.
However, these aren't approved as part of the UK's cervical screening programme, so you should still attend a smear test when you're invited by your GP.
View More »
Dr Grant says: 'Ultimately, women should choose the testing method that best suits their needs and provides the most comfort. However, the importance of regular screening, be that at home or with a GP, should never be undermined.'
Do you have a story to share?
Get in touch by emailing MetroLifestyleTeam@Metro.co.uk.
MORE: Jessie J shares health update with a trigger warning after breast cancer operation
MORE: The biggest pros and cons of weight loss jabs as NHS begins mass Mounjaro rollout
MORE: Everything we know so far about the NHS maternity investigation
Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
2 hours ago
- Daily Mirror
Woman told 'lumpy boobs' were normal but it was cancer
Lea Hughes was first reassured after spotting a small lump on her right breast aged 29 A woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as 'lumpy boobs' for two years. Lea Hughes, 38, first noticed a small lump on her right breast at the age of 29 but was reassured that her 'lumpy boobs' were merely hormonal. However, two years later, she noticed the lump had developed into a 'dimple'. On this occasion, doctors immediately referred her for a mammogram, ultrasound and biopsy. She was diagnosed with stage four breast cancer, which had spread to her liver and bones during the years it went undetected. Faced with an 'incurable' diagnosis, Lea pursued medications, therapies, and treatments to stabilise the disease and prevent further spread. But in August 2024, a scan revealed the cancer had reached her brain, and by March, it had also invaded her lungs. Lea, originally from the Wirral but now residing in Leytonstone, East London, has exhausted all NHS-funded treatment options and is now fundraising for private care. The former-fashion and retail marketer recalled: "When the doctor first told me I had lumpy boobs, I'd never heard of it before. But years on, I saw the lump had grown when I was putting a bikini on and I spotted a shadow caused by the lump. "Within weeks, I was diagnosed with stage four incurable cancer aged 31. Treatments contained it - until August 2024 - and now it's in my brain and lungs too. "I know the doctors and nurses so well now, after seven years at St. Bartholomew's Hospital, London. It's longer than any relationship I've ever had." Lea first spotted a small lump on the front of her right breast in 2015 and quickly sought medical advice. However, she was initially dismissed with the explanation that she simply had 'lumpy boobs' and at 29, without a family history, she wasn't eligible for further tests. Despite her attempts to get the issue addressed, it wasn't until a holiday in early 2018 that doctors took notice. She recalled noticing a shadow and a dimple while wearing a bikini, which led to an immediate referral to the hospital when she reported it over the phone. She underwent a series of examinations: "I went for a mammogram and an ultrasound, then a biopsy. When it came back as cancer, they did a breast MRI scan and noticed a shadow on my liver in the corner." Further investigations revealed the extent of her condition: "So they did full body scans - MRIs, PETs and bone scans - and learned it had spread to my liver and bones." Lea received a grim diagnosis of stage four incurable cancer in April 2018, coincidentally on Friday 13th. Treatment commenced at St. Bartholomew's Hospital, aiming to stabilise and contain the cancer. In June 2022, she underwent a single mastectomy. Unfortunately, one of the oral treatments proved too much for her body, resulting in hospitalisation in August 2023 due to severe side effects. She shared the harrowing experience: "I had hypercalcaemia - high calcium levels in the blood - and needed multiple blood transfusions. "It felt very real - I realised that this illness really could take me out." After opting for IV chemotherapy for 10 months, doctors successfully brought her cancer under control, allowing her to finish the treatment in May 2024. However, a routine scan in August 2024 revealed that her liver tumours had started to progress again, prompting a full-body scan to evaluate her eligibility for a new clinical trial. Unfortunately, this same scan uncovered that the cancer had also invaded her brain. Lea reflected on the discovery, sha ring: "It's one of those things, with stage four breast cancer, you know it can spread to the brain and you do worry. But I didn't expect it then, because I had no symptoms at all." Come September 2024, Lea began whole-brain radiotherapy before undertaking another series of IV chemotherapy treatments. Following this was radiotherapy targeting her spine, but by December 2024, her physical strength waned significantly as her body started to "give up". She recounted: "I'm 5ft 10ins and I went down to 7st. I was too weak to hold myself up - I was watching myself waste away. "I had to shave my head when I started losing my hair too. I didn't recognise myself and seeing those changes was very confronting." A brief period of improvement came in January 2025, but complications arose in March when she experienced serious breathing difficulties. The cancer had spread to her lungs, from which 4.5 litres of fluid were drained. Lea is now undergoing her sixth round of chemotherapy and has started fundraising efforts to access Enhertu, a targeted cancer therapy. Despite its availability on the NHS for certain types of breast cancer, Lea's extensive spread of the disease, including to her brain, leaves her ineligible for NHS-provided access to this particular drug. She holds onto hope that the drug, Enhertu, could be a game-changer for her brain cancer too as it's known to cross the blood-brain barrier – a rare trait not seen in many chemotherapy treatments. According to results gleaned from the DESTINY-Breast12 trial by creators AstraZeneca and Daiichi Sankyo, Enhertu revealed promising outcomes with a 61.6% one-year progression-free survival rate for patients who had both brain metastases and breast cancer. Yet, the steep cost of over £10,000 per cycle stands as a significant hurdle without NHS funding. Lea said: "I always try to lean into the positive - accepting how sh***y this is, but also not giving in. Yet the harshness of reality hits hard when treatments fail." Reflecting on her ordeal, she expressed disbelief: "I can't believe everything I've been through - you don't realise until you sit back and reflect. But I have no choice just to get on with it and keep fighting." Click to support her journey via fundraising here.
Daily Mirror
3 hours ago
- Daily Mirror
Woman dies from blood clot after taking common contraceptive used by millions
Chloe Alicia Ellis, 29, died three days after she was wrongly diagnosed and discharged from hospital. She had earlier been diagnosed as having a suspected pulmonary embolism in an online assessment after she collapsed at home A young woman tragically died three days after being misdiagnosed with a viral illness and subsequently discharged from hospital, said a coroner. Chloe Alicia Ellis, a 29 year old wildlife officer, had previously been identified as potentially having a pulmonary embolism during an online assessment, but this crucial information was not available to the medical staff when she visited Dewsbury and District Hospital. Chloe had complained of chest and back pain, as well as breathlessness. During an NHS 111 online assessment, she disclosed her history of using the Yasmin contraceptive pill to manage her endometriosis, an inquest in Wakefield was told. Following the assessment on 31 August last year, she was advised to visit A&E due to the algorithm's conclusion that she might have a pulmonary embolism. However, Chloe herself was not informed of this potential diagnosis. Regrettably, the results of the NHS online assessment were not accessible to the staff at Dewsbury Hospital. The inquest heard that an 'inadequate' history was taken from Chloe, as she was not questioned about her medication history or specifically her use of oral contraception. Inadequate history taking The hospital Trust has since implemented measures to address this issue of inadequate history taking, reports Yorkshire Live. Chloe, who was married, was diagnosed with a viral illness at Dewsbury Hospital and sent home. She collapsed at home on 3 September and, despite the best efforts of paramedics and clinicians at Leeds General Infirmary, she died later that day. The death of a young woman was caused by a pulmonary embolism, with the contributory factor being endometriosis treatment via the oral contraceptive pill. Coroner Oliver Longstaff has since acted, by contacting the West Yorkshire Integrated Care Board, issuing a stark warning to help prevent similar tragedies in the future. At the heart of the coroner's report is the revelation that Chloe's life might have been saved if Dewsbury hospital staff had been alerted to her history with the contraceptive pill. In his conclusion, the coroner made it clear: "...had a history of her oral contraceptive use been obtained when Chloe attended a local hospital Emergency Department on 31 August 2024, she would have been given anticoagulation medication and undergone tests that would have revealed the pulmonary embolism. "She would have received effective treatment for the pulmonary embolism and, on the balance of probabilities, would not have died three days later." Serious concerns During the inquest, Mr Longstaff voiced four serious concerns regarding the events leading up to Chloe's death. It was disclosed at the inquest that while it is technically feasible for NHS 111 online assessment outcomes to be shared with A&E staff, whether this happens is decided by the local Integrated Care Board. Furthermore, the panel learned that connectivity to NHS 111 online assessments had not been established for the Mid Yorkshire Teaching NHS Trust, which administers Dewsbury hospital, due to decisions made by the West Yorkshire Integrated Care Board. The coroner has highlighted that if the NHS online assessment completed by Chloe had been accessible to the medical staff at Dewsbury District Hospital, they would have been aware of her use of oral contraceptives and the suspected pulmonary embolism. The coroner remarked: "The availability of NHS 111 online assessments to clinicians in emergency departments may assist in the obtaining of a full history and may act as a failsafe against inadequate history taking in Emergency Departments." Mr Longstaff has requested a response from the West Yorkshire Integrated Care Board to his Prevention of Future Deaths report by August 8. Regret Expressing regret over the incident, the NHS West Yorkshire Integrated Care Board stated: "We are very sorry to hear about what happened to Chloe, and our sincere condolences go to her loved ones. "We have been reviewing the points raised by the Coroner and we are working with all our relevant partners to understand the learning and the current arrangements to establish what changes are required in order to prevent similar losses in future." In the wake of Chloe's heartbreaking passing, her friends, family, and colleagues have rallied behind a charity walk in her honour. The Dozy Wanderers walk aims to gather £5,000 by trekking 213 miles from Ingleborough to Scarborough, passing through a nature reserve in Hull known as Paull Holme Strays. Wildlife defender Yorkshire Wildlife Trust, where Chloe had been a fervent wildlife advocate, is among the charities set to benefit from her legacy. Chloe held a university degree and had experience as a planning officer for a local authority in West Yorkshire. A charity spokesperson expressed to Yorkshire Live how much of a dedicated wildlife champion Chloe was. "A keen defender and champion of wildlife, Chloe was a planning advocate at Yorkshire Wildlife Trust, responding to applications, including those that could have a detrimental impact on the Trust's nature reserves and Yorkshire's wildlife. "Her commitment to defending nature and her ability to navigate complex ecological and policy matters led to a number of successes for the Trust." Rachael Bice, CEO at Yorkshire Wildlife Trust, shared: "Chloe was a delight to work with and is dearly missed by us all. She was always enthusiastic in sharing her knowledge and experience to defend nature; a true natural advocate for wildlife. We will continue to honour Chloe's memory by upholding the values she championed and by striving to protect the natural world she loved so dearly." Chloe's passion The Trust praised Chloe's "passion for wildlife and dedication to our cause were truly inspiring, with her work being instrumental in securing a safe future for Yorkshire's wildlife." Yorkshire Wildlife Trust has expressed its heartfelt support for the Dozy Wanderers' fundraising initiative in memory of Chloe Ellis, a cherished colleague who tragically passed away last year at just 29 years old. In a social media post, the trust stated: "We at Yorkshire Wildlife Trust are deeply moved by the Dozy Wanderers' heartfelt initiative to raise funds in memory of our beloved colleague, Chloe Ellis, who tragically passed away last year at the age of 29." The trust highlighted Chloe's remarkable dedication to wildlife conservation, saying: "Chloe's passion for wildlife and dedication to our cause were truly inspiring, with her work being instrumental in securing a safe future for Yorkshire's wildlife." Ambitious trek The Dozy Wanderers' ambitious 203-mile trek from Ingleborough to Paull Holme Strays in Hull, concluding in Scarborough in July 2025, aims to raise £5,000 for Yorkshire Wildlife Trust and Dementia UK. The trust urged everyone to rally behind the cause, stating: "Let's honour Chloe's memory and support these amazing causes together." The Just Giving page has already garnered over £4,000 from 90 supporters, with the funds being split between Yorkshire Wildlife Trust and Dementia UK. The Just Giving page can be found here. Tributes have been pouring in on the page, with one donor writing: "For beautiful Chloe. Always in our hearts." Another supporter shared: "For beautiful Chloe. May you always smile down on us. Missed every day. Loved for always." A well-wisher added: "Good luck. Chloe was a lovely young lady."
Daily Mail
3 hours ago
- Daily Mail
Woman's common sex problem turned out to be deadly cervical cancer...as smear tests are to be given LESS often
A woman hit with advanced cervical cancer at 25 has urged others to attend every screening test—after she delayed her smear due to fears sparked by 'online horror stories'. Jasmin McKee, now 26, from Southampton, began suffering lower back pain and bleeding after sex in 2023, but assumed it was due to her newly-fitted copper coil. The operations manager had also 'put off' her cervical screening after reading fear-mongering stories online that suggested the procedure was painful. But in March 2024, she eventually plucked up the courage to attend the test which, to her horror, confirmed she had the cancer-causing virus, human papillomavirus (HPV). Around 99 per cent of all cervical cancers are caused by the HPV virus, which can be spread via sexual contact. Doctors also discovered that Ms McKee had abnormal cell changes within her cervix, with a later biopsy confirming the presence of cancer. Further scans showed the disease was stage three, meaning it had spread to nearby tissues. Around 60 per cent of those diagnosed at this stage won't survive for longer than five years, according to Cancer Research UK. 'Everything just goes a bit numb… it's just such a big shock,' she said of learning the devastating news. 'I didn't want the people that I love the most feeling sad for me. I just didn't want them to worry.' She immediately regretted delaying her screening test. 'It was nothing to worry about,' she said. 'I was in and out in 10 minutes and, for me, it was painless. '[Cervical screening tests] are not an embarrassing thing, the nurses will do 20 of them a day, no one cares. 'It's so quick, it's nothing to be scared about and they can save your life.' Ms McKee underwent surgery in November last year to try and remove the tumour, but doctors were unable to destroy it completely—and it continued to grow. In January this year, she began radiotherapy, five days a week for three weeks, and decided to tell her family about her diagnosis. Unfortunately, scans revealed the radiotherapy had not been effective, and chemotherapy was needed, which she underwent in April. She is currently having eight rounds of chemotherapy every three weeks, and is expected to finish treatment in early September 2025. 'Once I'm better, I'm going to grab every opportunity and get as much happiness out of life as possible,' she said. Ms McKee's story comes in the same week NHS England announced low-risk women aged 25-49 in England will now be invited for cervical screenings every five years, as opposed to every three. This change will bring cervical screening in England in line with Scotland, Wales, and other European countries, and aligns screening intervals to that of women aged 50 to 64. Those who test positive for HPV will be invited back for further checks, more often. The approach is based on evidence and expert recommendation from the UK National Screening Committee and is based on analysis from King's College London showing five-yearly screening is just as safe as three-yearly, with the same number of cancers found. The NHS say that, while the health service recognises changes to cervical screening can 'seem worrying', the new approach is based on robust scientific evidence and an expert recommendation from the UK National Screening Committee. 'The NHS cervical screening programme tests for human papillomavirus (HPV) and uses a better and more accurate test than before,' said a spokesperson. 'This means if you test negative for HPV, you don't need to be screened as often as your risk of developing cervical cancer is very low. 'If you test positive for HPV, we'll monitor you more closely with additional tests and follow-up appointments. 'This personalised approach ensures everyone receives the right level of screening based on their individual risk factors, providing better protection while reducing unnecessary procedures.' The NHS website says anyone worried about symptoms of cervical cancer should see their GP. Typical signs include unusual vaginal bleeding—such as during or after sex, between periods or after the menopause—pain during sex or in the lower back, pelvis and/or tummy, and changes to vaginal discharge. Research published last year found the UK death rate among women from cervical cancer has dropped by 54 per cent over the last 25 years. Experts say this is mostly due to of the HPV vaccine, which is given to teenagers and reduces cervical cancer risk by 90 per cent. In 2023 NHS England announced a plan to 'eliminate' cervical cancer by 2040, aiming for a prevalence rate of below four per every 100,000 people.
